Home › Trial NCT06530784
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
- Trial IDNCT06530784
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorShanghai Zhongshan Hospital
- Enrollment36
- Start date2024-07-31
- ConditionsCarcinoma, Hepatocellular
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.